SG11202106708VA - Method of predicting for benefit from immune checkpoint inhibition therapy - Google Patents
Method of predicting for benefit from immune checkpoint inhibition therapyInfo
- Publication number
- SG11202106708VA SG11202106708VA SG11202106708VA SG11202106708VA SG11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA
- Authority
- SG
- Singapore
- Prior art keywords
- predicting
- benefit
- immune checkpoint
- inhibition therapy
- checkpoint inhibition
- Prior art date
Links
- 230000005746 immune checkpoint blockade Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Data Mining & Analysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201811546W | 2018-12-21 | ||
PCT/SG2019/050629 WO2020130948A1 (en) | 2018-12-21 | 2019-12-20 | Method of predicting for benefit from immune checkpoint inhibition therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106708VA true SG11202106708VA (en) | 2021-07-29 |
Family
ID=71102946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106708VA SG11202106708VA (en) | 2018-12-21 | 2019-12-20 | Method of predicting for benefit from immune checkpoint inhibition therapy |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220081723A1 (en) |
EP (1) | EP3899019A4 (en) |
JP (1) | JP2022515416A (en) |
KR (1) | KR20210148077A (en) |
CN (1) | CN113692449A (en) |
SG (1) | SG11202106708VA (en) |
WO (1) | WO2020130948A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116200498A (en) * | 2023-03-14 | 2023-06-02 | 广州希灵生物科技有限公司 | Prognosis biomarker for gastric cancer patients and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3090065B1 (en) * | 2013-12-30 | 2019-12-11 | Agency For Science, Technology And Research | Methods for measuring biomarkers in gastrointestinal cancer |
US20170275705A1 (en) * | 2014-09-15 | 2017-09-28 | The Johns Hopkins University | Biomarkers useful for determining response to pd-1 blockade therapy |
ES2767730T3 (en) * | 2015-04-30 | 2020-06-18 | Univ Kyoto | Method to predict the therapeutic effect of PD-1 / PD-L1 inhibitor using PD-L1 (CD274) abnormality as index |
AR105618A1 (en) * | 2015-05-29 | 2017-10-25 | Genentech Inc | METHODATION OF THE PROMOTER OF THE BINDING TO THE PROGRAMMED DEATH RECEIVER (PD-L1) IN CANCER |
SG11201806946VA (en) * | 2016-02-16 | 2018-09-27 | Agency Science Tech & Res | Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma |
-
2019
- 2019-12-20 EP EP19898711.7A patent/EP3899019A4/en active Pending
- 2019-12-20 CN CN201980092626.0A patent/CN113692449A/en active Pending
- 2019-12-20 JP JP2021536739A patent/JP2022515416A/en active Pending
- 2019-12-20 US US17/416,903 patent/US20220081723A1/en active Pending
- 2019-12-20 KR KR1020217023202A patent/KR20210148077A/en active Search and Examination
- 2019-12-20 SG SG11202106708VA patent/SG11202106708VA/en unknown
- 2019-12-20 WO PCT/SG2019/050629 patent/WO2020130948A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113692449A (en) | 2021-11-23 |
KR20210148077A (en) | 2021-12-07 |
US20220081723A1 (en) | 2022-03-17 |
WO2020130948A1 (en) | 2020-06-25 |
EP3899019A4 (en) | 2022-10-05 |
EP3899019A1 (en) | 2021-10-27 |
JP2022515416A (en) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202105109PA (en) | Method for detection of rna | |
PT3322731T (en) | Method of treating cancer using immune checkpoint inhibitor | |
EP3524689C0 (en) | Method for predicting the prognosis of breast cancer patient | |
IL278967A (en) | Biomarkers for determining the effectiveness of immune checkpoint inhibitors | |
IL267885B (en) | Methods and systems for computer-based determining of presence of objects | |
IL290266A (en) | Biomarkers for determining the efficacy of immune checkpoint inhibitors | |
SG11202006997SA (en) | A method of determining a risk of cancer | |
GB2576553B (en) | Method of hologram calculation | |
SG11201912200YA (en) | Method for treating a side effect of immunotherapy | |
SG11202106708VA (en) | Method of predicting for benefit from immune checkpoint inhibition therapy | |
GB201704115D0 (en) | Method of selecting for antibodies | |
GB2580539B (en) | Method for co-processing | |
SG11202102582TA (en) | Method and system of targeting epitopes for neoantigen-based immunotherapy | |
GB2536492B (en) | Method of laying lined pipeline | |
GB201906201D0 (en) | Method for the detection of protate cancer | |
SG11202105877YA (en) | Method of treatment | |
IL261475A (en) | Method of identifying optimal zones for electropulse therapy (variants) | |
GB201704386D0 (en) | Method for identification of sofosbuvir resistant patients | |
GB201617722D0 (en) | Method for determining prognosis of cancer | |
GB201914079D0 (en) | Method of predicting requirement for biologic therapy | |
SG11202101817UA (en) | Methods of inhibition | |
GB201815409D0 (en) | Computer-Implemented methods for predicting psychological therapy outcome | |
GB201800556D0 (en) | Computer-implemented methods for predicting psychological therapy outcome | |
ZA202001642B (en) | Method for the treatment of iron-containing sludge | |
GB201906199D0 (en) | Method for the detection of cancer |